Mobile App

Google Play Apple Store
Advances in the Management of Chronic Immune Thrombocytopenia in Adults - Updated 9/1/20
Certified CME/CNE Activity - Mini Modules
Chronic immune thrombocytopenia (ITP) is one of the most common causes of thrombocytopenia in adults. Diagnosis of ITP remains one of exclusion, and differential diagnosis with secondary forms is crucial to exclude other forms of thrombocytopenia, which may require a different therapeutic approach. Furthermore, chronic symptomatic ITP necessitates second-line treatments based on highly individualized considerations. Advances in the understanding of the pathogenesis have led to novel therapeutic targets, such as the thrombopoietin receptor agonists to aid in this personalized approach.

These educational Mini Modules will outline recent data on current and emerging treatment options for chronic ITP, including FcRn and spleen tyrosine kinase inhibitors.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.
Review one (or all) Mini Modules of interest. Claim AMA or ANCC credit/contact hour(s) per module after completion of each brief Post-Test/Evaluation.
Hanny Al-Samkari, MD
Hanny Al-Samkari, MD
Instructor in Medicine
Harvard Medical School
Attending Hematologist and Clinical Investigator
Massachusetts General Hospital




20
Supported by an independent educational grant from Dova Pharmaceuticals
December 31, 2020
Mini Module
6432
MiniModules_WebBannerCITP(1158px).gif
Hematology-Oncology